Shares in Novo Nordisk, maker of the wildly popular obesity drug Wegovy were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli ...
LONDON - Shares in Novo Nordisk , maker of the wildly popular obesity drug Wegovy were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly 's own treatment Mounjaro leads to faster and greater weight loss .
After accounting for individual risk factors, patients taking Mounjaro were 76% more likely to lose at least 5% of their body weight, more than twice as likely to lose at least 10%, and more than three times as likely to lose at least 15%, compared to patients taking Ozempic, the report found.
Shares in Novo and Lilly are at record highs on profits from the weight-loss drugs. Although Novo's Wegovy has been on the market in the United States since 2021, Lilly's version, sold as Zepbound in the U.S., only launched there late last year.A mum was heartbroken when her "perfect" tot was diagnosed with childhood Alzheimer's - after she spotted an identical looking girl on TikTok.
Novo Nordisk Weight Loss JAMA Internal Medicine Weight-Loss Drugs Data Analysis Health Records Patients Body Weight
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk, Eli Lilly still top 2 pharma stocks: AnalystNovo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as...
Read more »
Eli Lilly and Novo Nordisk are a 'duopoly' in GLP-1 marketGLP-1 weight-loss drugs have been major revenue generators for pharmaceutical companies such as Eli Lilly (LLY) and Novo Nordisk (NVO). Goldman Sachs US Lead...
Read more »
Novo Nordisk stock rises on Wegovy approval in ChinaShares of Novo Nordisk (NVO) are soaring to an all-time high after its popular GLP-1 weight-loss drug, Wegovy, was approved in China. Yahoo Finance's Anjalee...
Read more »
Ozempic Maker Novo Nordisk Plans Another $4.1 Billion US FactoryNovo Nordisk A/S plans to invest $4.1 billion in another US factory, plowing more money into its biggest market amid rising discontent there over the cost of its obesity and diabetes drugs.
Read more »
Novo Nordisk says no sign of crime, links between fires at Danish facilities over past monthA fire at a building near the company’s Bagsvaerd head office northwest of Copenhagen on Tuesday was the third in just over one month at different facilities occupied by Novo Nordisk
Read more »
Blaze at Danish drugmaker Novo Nordisk is the third in a little over a monthCOPENHAGEN, Denmark (AP) — A fire broke out Tuesday at an office building belonging to Danish pharmaceutical company Novo Nordisk, the third in a little more...
Read more »